Daryl Gaugler
CIK 1928278 · Chief Operating Officer · last filed 2025-01-06
Daryl Gaugler is a Chief Operating Officer who has filed 19 SEC Form 4 insider transactions across 1 company since 2022. The most recent filing, for PCRX, was dated Mar 6, 2025. Across all open-market trades the lifetime net is −$327.8K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $4.2M across reported positions. 20 SEC filings were submitted jointly with Pacira BioSciences, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PCRX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
5401 WEST KENNEDY BOULEVARD, SUITE 890
TAMPA, FL 33609
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PCRX | Chief Operating Officer | 115,443 | $36.46 | $4.21M | -$327.8K | 11 | 2025-01-06 |
Recent Filings
19 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-03-06 | PCRX | Notice (144) | −500 | -$11.6K | EDGAR |
| 2025-01-06 | PCRX | Grant (A) | +243 | $3.9K | EDGAR |
| 2024-12-16 | PCRX | Sell (S) | −500 | -$9.9K | EDGAR |
| 2024-12-13 | PCRX | Notice (144) | −500 | -$9.9K | EDGAR |
| 2024-09-13 | PCRX | Notice (144) | −500 | -$6.4K | EDGAR |
| 2024-09-13 | PCRX | Sell (S) | −500 | -$6.4K | EDGAR |
| 2024-07-03 | PCRX | Grant (A) | +160 | $3.9K | EDGAR |
| 2024-06-13 | PCRX | Notice (144) | −1,000 | -$28.4K | EDGAR |
| 2024-06-13 | PCRX | Mixed | +53,300 | -$28.4K | EDGAR |
| 2024-06-05 | PCRX | Tax (F) | −2,754 | -$85.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.